Liu, Yu-Chin
Lin, Yang-Hsiang
Chi, Hsiang-Cheng
Huang, Po-Shuan
Liao, Chia-Jung
Liou, Yu-Syuan
Lin, Chiao-Chun
Yu, Chia-Jung
Yeh, Chau-Ting
Huang, Ya-Hui
Lin, Kwang-Huei
Funding for this research was provided by:
Ministry of Education (EMRPD1L0351)
Ministry of Science and Technology, Taiwan (MOST 107-2314-B-182A-126-MY2, MOST 106-2320-B-182-031-MY3)
Chang Gung Memorial Hospital, Linkou (CMRPD1L0111)
Article History
Received: 18 April 2022
Accepted: 9 August 2022
First Online: 23 August 2022
Declarations
:
: All the paired human HCC specimens were obtained from the Taiwan Liver Cancer Network (TLCN). The protocol was approved by the Medical Ethics and Human Clinical Trial Committee at Chang-Gung Memorial Hospital (IRB: 202000434B0). Animal treatments were performed following the Guideline of Experimental Animal Ethics Committee of the Chang-Gung University (IACUC Approval No.: CGU108-015).
: All authors have read and approved the manuscript including content and presentation to the clinical epigenetic.
: The authors have no competing interests to disclose.